Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade

Core Viewpoint - DiaMedica Therapeutics, Inc. (DMAC) has shown a significant price increase of 31.5% over the past four weeks, with a mean price target of $12.33 indicating a potential upside of 100.8% from its current price of $6.14 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $1.53, where the lowest estimate of $11.00 suggests a 79.2% increase, and the highest estimate of $14.00 indicates a potential surge of 128% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement direction and magnitude, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Agreement - There is increasing optimism among analysts regarding DMAC's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has risen by 9.7% over the past month, with one estimate increasing and no negative revisions [10] Zacks Rank and Investment Potential - DMAC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [11] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for potential investment decisions [12]